Physiomics plc (AIM:PYC), a mathematical modelling, data science and biostatistics company, said on Thursday that it has signed a new contract with Swiss biotechnology company Numab Therapeutics AG to support preclinical development of a multi-specific antibody for autoimmune diseases.

The collaboration will employ modelling and simulation to develop a mechanistic pharmacokinetics and pharmacodynamics (PK/PD) model, guiding drug behaviour analysis and dosing selection for preclinical and clinical studies.

The project is scheduled for delivery within the financial year ending 2026.

Physiomics highlighted that this work reinforces the importance of Model Informed Drug Development approaches across the drug development lifecycle, particularly in preclinical research.